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Autoimmune rheumatic disease 
IgG has differential effects upon 
neutrophil integrin activation that 
is modulated by the endothelium
Akif A. Khawaja1,2, Charis Pericleous3, Vera M. Ripoll2, Joanna C. porter  1 & Ian p. Giles2
The importance of neutrophils in the pathogenesis of autoimmune rheumatic diseases, such as systemic 
lupus erythematosus (SLE) and rheumatoid arthritis (RA), is increasingly recognised. Generation 
of reactive oxygen species (ROS) and release of neutrophil extracellular traps (NETs) by activated 
neutrophils are both thought to contribute to pathology; although the underlying mechanisms, 
particularly the effects of IgG autoantibodies upon neutrophil function, are not fully understood. 
Therefore, we determined whether purified IgG from patients with SLE or RA have differential effects 
upon neutrophil activation and function. We found that SLE- and RA-IgG both bound human neutrophils 
but differentially regulated neutrophil function. RA- and SLE-IgG both increased PMA-induced β1 
integrin-mediated adhesion to fibronectin, whilst only SLE-IgG enhanced αMβ2 integrin-mediated 
adhesion to fibrinogen. Interestingly, only SLE-IgG modulated neutrophil adhesion to endothelial cells. 
Both SLE- and RA-IgG increased ROS generation and DNA externalisation by unstimulated neutrophils. 
Only SLE-IgG however, drove DNA externalisation following neutrophil activation. Co-culture of 
neutrophils with resting endothelium prevented IgG-mediated increase of extracellular DNA, but this 
inhibition was overcome for SLE-IgG when the endothelium was stimulated with TNF-α. This differential 
pattern of neutrophil activation has implications for understanding SLE and RA pathogenesis and may 
highlight avenues for development of novel therapeutic strategies.
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are both autoimmune rheumatic diseases 
(ARDs) that share features of endothelial dysfunction, aberrant leukocyte activation and pathogenic autoanti-
body formation, all of which contribute to pathophysiology. Increasingly, neutrophil dysfunction has also been 
recognised in ARD immunopathology1,2.
Neutrophils are rapidly recruited to sites of infection or inflammation, where complex interactions between 
neutrophil selectins and integrins with their endothelial ligand counterparts regulate neutrophil extravasation and 
activation. Activated neutrophils fight infection and promote inflammation via phagocytosis, degranulation and 
neutrophil extracellular trap (NET) formation. NET release results in the externalisation of a meshwork of chro-
matin fibres decorated with antimicrobial proteins and proteases, via a process termed NETosis3. NETs ensnare 
bacteria and promote pathogen killing, but also expose neo-antigens and pro-inflammatory molecules. Aberrant 
NETosis can induce endothelial damage and dysfunction4,5, leading to increased risk of atherosclerosis and vas-
cular thrombosis6,7. Moreover, NETs have been demonstrated to activate both leukocytes8–11 and stromal cells12, 
which can drive disease progression. Dysregulation of this process has been implicated in both SLE and RA13–15.
Neutrophils express several different classes of integrins but the most important are the β1 and β2 integrins. The 
β1 integrins recognise ligands in the extracellular matrix (ECM), in particular those with the Arg-Gly-Asp (RGD) 
motif (found in fibronectin, vitronectin and laminin). As well as recognising RGD, α4β1 has a ligand-binding site 
for Leu-Asp-Val-Pro (LDVP) and Ile-Asp-Ala-Pro (IDAP) found in fibronectin. In addition, α4β1 can also bind 
the Ile-Asp-Ser-Pro (IDSP) motif found in vascular cell adhesion molecule (VCAM)-116, a ligand that is upreg-
ulated on endothelial cells during inflammation. The β2 integrin αLβ2 binds intercellular cell adhesion molecule 
1centre for inflammation and tissue Repair, University college London, London, United Kingdom. 2centre for 
Rheumatology, University college London, London, United Kingdom. 3national Heart and Lung institute, imperial 
college London, London, United Kingdom. Joanna c. Porter and ian P. Giles contributed equally. correspondence 
and requests for materials should be addressed to i.P.G. (email: i.giles@ucl.ac.uk)
Received: 15 May 2018
Accepted: 24 October 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts |          (2019) 9:1283  | https://doi.org/10.1038/s41598-018-37852-5
(ICAM)-1, a ligand that is upregulated on various cell types following inflammation. In contrast, αMβ2 is more 
promiscuous and recognises a range of ligands including ICAM-1 and fibrinogen, which are upregulated at sites 
of tissue injury and during active coagulation. Integrin-mediated adhesion, via β1 and/or β2 integrins, is vital to 
neutrophil activation17, leading to the production of reactive oxygen species (ROS) and NETosis18–21. Moreover, 
evidence indicates that integrin inhibition reduces NET release15,20.
ARDs are generally characterised by immune dysfunction, with many groups exploring the immune differ-
ences in patients with SLE and RA. Given the presence of autoantibodies, it is unsurprising to find that defects 
in B and T cell regulation have been described in both SLE and RA. B cells contribute to pathology not only 
through antigen presentation, but also by producing autoantibodies22. Studies in RA found that autoantibodies 
stimulate the production of pro-inflammatory cytokines22, which promote T cell, B cell and macrophage activa-
tion22,23. Greater peripheral B cell activation was observed in patients with SLE24, with cells being more sensitive 
to cytokine stimulation25, displaying abnormal receptor-mediated signalling26 and having a greater propensity to 
undergo epitope spreading27.
Th1 cells have conventionally been considered to drive RA pathology, however there is growing interest in 
other T cell subsets. Th17 cells secrete pro-inflammatory mediators that suppress regulatory T cell (Treg) gen-
eration28,29. Elevated Th17 and reduced Treg differentiation have been described in RA patients, which promote 
inflammatory cell phenotypes30. In addition, Tregs isolated from RA patients have limited suppressive activity31,32, 
which is attributed to low expression of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)32. This reduced 
Treg population, with defective suppressive capability, fails to suppress autoreactive T cells33. Aberrant T cell 
activation has also been linked to SLE pathology, with reports documenting abnormal TCR signalling and T cell 
hyper-responsiveness arising through defects in an array of signalling molecules34–39.
Macrophages also contribute to RA pathology through pro-inflammatory cytokine production, ROS gener-
ation, release of matrix-degrading enzymes, phagocytosis and antigen presentation40. Monocytes isolated from 
SLE patients have elevated expression of activation markers and adhesion molecules41–44. Aberrant cytokine pro-
duction has also been described in SLE-derived monocytes25,45,46, which promote the production of anti-dsDNA 
autoantibodies by B cells47,48.
Studies identified neutrophils in the synovial fluid of RA patients49–51, with further reports finding increased 
neutrophil activation52–54. Neutrophils have also been implicated in RA mouse models55–57. RA neutrophils 
are prone to spontaneous NETosis, with elevated NETs being reported in RA serum that correlated with 
anti-citrullinated protein antibodies (ACPA) titres and markers of inflammation14. Adaptive immunity has an 
established role in SLE pathology, however in more recent years, neutrophils are being increasingly studied. Early 
studies noted that SLE sera induced neutrophil aggregation and interfered with phagocytosis and degranula-
tion58. Uptake of circulating nucleosomes activates neutrophils59, which leads to the secretion of antibacterial 
proteins. Elevated bactericidal proteins have been documented in SLE serum, which correlate with autoantibody 
titres60 and disease activity61–63. NETosis releases dsDNA and inflammatory cytokines, which also correlate with 
anti-dsDNA antibodies titres64.
The presence of circulating autoantibodies in SLE and RA is well-established, and used to aid diagnosis, pre-
dict disease progression and monitor response to treatment. Patients with either SLE or RA commonly present 
with a multitude of autoantibodies, with a large heterogeneity of antigenic targets65,66, each believed to confer 
pathogenic effects. Early reports found that sub-fractions of SLE-IgG were able to activate cultured endothe-
lial cells and promote adhesion of the monocytic U937 cell line67. Some groups have specifically examined the 
effects of IgG upon neutrophil activation, highlighting an increased propensity of patient-derived neutrophils 
to undergo spontaneous NETosis as well as serum IgG being able to induce NET release14,68–70. However, whilst 
these studies report IgG effects upon an end-stage functional outcome of neutrophil activation (NETosis), there 
does not appear to be any evidence examining involvement of β1 and β2 integrins, which occurs at an early stage 
of neutrophil activation.
The precise effects of purified ARD-IgG upon neutrophil integrin activation and adhesion are poorly char-
acterised. Given the importance of neutrophil activation to ARD immunopathology, determining the effects 
of ARD-IgG upon neutrophil function may elucidate the mechanisms through which neutrophils contribute 
to disease progression. Therefore, we examined the effects of SLE- and RA-IgG on β1 and β2 integrin-mediated 
adhesion and activation.
Results
Patient demographics. Neutrophils were isolated from 12 healthy controls (HCs), 12 SLE patients and 7 
RA patients. IgG was purified from a separate cohort of 9 HCs, 5 SLE patients and 9 RA patients. Demographics, 
clinical history and treatments of all subjects at the time of sample collection are listed in Table 1. All purified IgG 
samples tested negative for both PR3- and MPO-anti-neutrophil cytoplasmic antibody (ANCA), which excluded 
any effects being mediated by these traditional anti-neutrophil antibodies. Only RA-IgG samples tested positive 
(>5 U/ml) for ACPA. Our SLE cohort displayed presented with a variety of manifestations: 59% presented with 
renal involvement; 29% had arthritis; 12% had pulmonary involvement and 24% presented with photosensitive 
rashes. All of our RA cohort presented with articular involvement. In addition, 13% were hypertensive, 13% pre-
sented with rheumatoid nodules and 25% had pulmonary involvement. All patient fulfilled relevant classification 
criteria with stable disease. Patients with active disease requiring medication change at the time of sampling were 
excluded.
Purified SLE- and RA-IgG both enhance hydrogen peroxide production. To examine whether 
there were intrinsic differences between neutrophils derived from our patient and control populations, we first 
examined hydrogen peroxide (H2O2) generation in ex vivo SLE-, RA- and HC-derived neutrophils. These exper-
iments demonstrated that SLE-neutrophils had significantly slower rates of H2O2 production compared to both 
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HC- and RA-neutrophils (Fig. 1A). We also found no significant difference between HC- and RA-neutrophils in 
our assay. To build on these experiments, we subsequently explored the effects of purified IgG upon neutrophils 
isolated from healthy volunteers, to determine whether the presence of autoantibodies drive the activated neu-
trophil phenotype reported among patient populations. Here, we found that pre-conditioning neutrophils with 
SLE- or RA-IgG induced significantly higher rates of H2O2 generation (Fig. 1B), indicating that the presence of 
autoreactive IgG may prime neutrophils to enhance H2O2 production following stimulation. We therefore found 
that whilst ex vivo SLE-neutrophils displayed slower rates of H2O2 generation, treatment with ARD-IgG increased 
H2O2 production rates in HC-neutrophils.
ARD-IgG binds neutrophils. To determine whether purified IgG bound neutrophils, we employed a flow 
cytometry approach. HC neutrophils were incubated with pooled IgG (5 different IgG samples per group), cho-
sen at random from each group, and stained for CD15 and human IgG. Neutrophils were then evaluated by flow 
cytometry, being selected based on their forward and side scatter properties (Fig. 1C). Gated neutrophils were 
subsequently analysed based on CD15 and the presence of human IgG, both in the absence and presence of FcR 
blockade (Fig. 1C). Greater numbers of CD15+IgG+ cells were observed with both SLE- and RA-IgG compared 
to HC-IgG (Fig. 1D). Building on this dataset, we also examined IgG binding in the presence of a FcR blocking 
reagent (Miltenyi, UK), which only reduced binding of SLE-IgG, indicating a contribution from FcγR-mediated 
interactions with this IgG source (Fig. 1E). Therefore, all subsequent functional studies were performed with 
FcγR blockade to specifically examine antigen-specific mediated effects.
ARD-IgG displays differential effects upon neutrophil adhesion and trans-endothelial migration. 
To evaluate whether β1 or β2 integrin-mediated adhesion were modulated by purified IgG, we evaluated neutro-
phil adhesion to their respective ligands, fibronectin (via β1 integrins) and fibrinogen (αMβ2 integrin) in the pres-
ence of individual SLE- (n = 5), RA- (n = 7) or HC-IgG (n = 6) samples. In the absence of phorbol 12-myristate 
13-acetate (PMA), the effects of SLE- and RA-IgG upon neutrophil adhesion to both fibronectin and fibrinogen 
were identical to those of HC-IgG (Fig. 2A,B). In contrast, following PMA stimulation, both SLE- and RA-IgG 
increased neutrophil adhesion to fibronectin (Fig. 2A) compared to HC-IgG. Interestingly, only SLE-IgG sig-
nificantly increased neutrophil adhesion to immobilised fibrinogen (Fig. 2B). The addition of pan-β1 integrin 
(P5D2) or αMβ2-specific (2LPM19c) blocking antibodies reduced PMA-induced binding to values similar to 
unstimulated cells (Fig. 2A,B). Thus, PMA-stimulated neutrophil adhesion to fibronectin was enhanced by both 
SLE and RA-IgG, but to fibrinogen by SLE-IgG only.
We then examined the modulatory effects of individual IgG samples upon unstimulated and PMA-induced 
neutrophil adhesion to human umbilical cord endothelial cells (HUVEC). Interestingly, only SLE-IgG signifi-
cantly enhanced both unstimulated and PMA-induced neutrophil adhesion to both resting and TNF-α-activated 
HUVEC compared to control IgG (Fig. 3A,B). In contrast, we found that neither SLE- nor RA-IgG affected basal 
or chemokine-induced neutrophil trans-endothelial migration compared to HC-IgG (Fig. 3C). Taken together, 
our data suggest that whilst RA- and SLE-IgG both enhanced PMA stimulated β1 integrin-mediated adhesion 
to fibronectin, only SLE-IgG significantly affected αMβ2-mediated adhesion to fibrinogen as well as cultured 
HUVEC.
Healthy Control SLE RA
Cohort size (n) 21 17 16
Age (years ± SD) 33 ± 8.1 38 ± 6.8 57 ± 9.1
Sex (M:F) 7:14 2:15 4:12
Clinical Features (n) — Joint (5), Lung (2), Renal (10), Skin (4) CVD (2), Joint (16), Lung (4), Skin (2)
Treatments (n) — Aspirin (8), HCQ (12), MMF (17), Pred (17), Tacrolimus (3)
Aspirin (1), HCQ (10), Humira (1), 
MTX (4), Pred (2), RTX (3), SSZ (1)
IgG Binding Characteristics
ACPA (U/ml) 2.16 ± 0.10 2.38 ± 0.34 124.76 ± 106.12
RF (% positive) 0 0 100
ANA (% positive) 0 100 22.2
Anti-dsDNA (% positive) 0 80 0
MPO-ANCA ns ns ns
PR3-ANCA ns ns ns
Table 1. Patient clinical and demographic data. Clinical details were recorded for all subjects. At the time 
of blood donation: 2 RA patients had cardiovascular features (hypertension), 16 RA and 5 SLE patients had 
inflammatory arthritis, 4 RA patients and 2 SLE patients had interstitial lung disease, 2 RA patients had 
rheumatoid nodules, 4 SLE patients had SLE-related rashes and 10 SLE patients had nephritis. Abbreviations: 
ACPA, anti-citrullinated protein antibody; ANA, anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic 
antibody; CVD, cardiovascular disease; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; MPO, 
myeloperoxidase; MTX, methotrexate; ns, not significant; PR3, proteinase 3; Pred, prednisolone; RF, 
rheumatoid factor; RTX, rituximab; SSZ, sulfasalazine.
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Figure 1. SLE- and RA-IgG both bind neutrophils and prime neutrophils. (A) Neutrophils were isolated from 
patients with SLE (n = 12) or RA (n = 7) and healthy volunteers (n = 12), and rates of H2O2 production in 
response to 50 nM PMA using Amplex UltraRed. Data are presented as each point representing a patient sample 
tested with the mean and SEM also being displayed and were analysed by Kruskal-Wallis test (p = 0.0039) with 
a Dunn’s multiple comparison test. (B) H2O2 generation in control neutrophils was assessed in the presence 
of ARD-IgG in the presence of 50 nM PMA. Data are displayed as the mean and SEM from three independent 
experiments, with each point representing the average of IgG sample over the experimental repeats. Data were 
analysed by Kruskal-Wallis test (p < 0.0001) with a Dunn’s multiple comparison test. (C) Representative flow 
cytometry plots examining binding for purified IgG to human neutrophils. Isolated neutrophils were incubated 
with pooled IgG, composed of 5 different IgG samples in the absence or presence of FcγR blockade, and stained 
for CD15 and human IgG. IgG binding was determined by quantifying the amount of CD15+IgG+ cell within 
the neutrophil gate (D) IgG binding experiments were performed using neutrophils from 9 different healthy 
donors, with mean and SEM being displayed. Statistical significance was tested by a Kruskal-Wallis (p = 0.0010) 
test with a Dunn’s multiple comparison test. (E) Additional experiments examined pooled IgG binding in 
the presence of FcγR blockade and the number of CD15+IgG+ cells quantified by flow cytometry. Data are 
presented as the mean and SEM of nine donors (with each point representing a different neutrophil donor), 
which were compared to the number of CD15+IgG+ cells previously determined. Data were tested by repeated 
measures two-way ANOVA a Bonferroni’s multiple comparison test. ns = no significance, *p < 0.05, **p < 0.01.
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ARD-IgG increases DNA release by neutrophils. We next examined whether IgG could also modulate 
the release of extracellular DNA, both in the absence (spontaneous) and presence of PMA (inducible). Using 
immunofluorescence staining for histone H3, we noted that PMA stimulation induced DNA externalisation, 
characteristic of NET release (Fig. 4A). Comparative analysis of neutrophil supernatants also showed a significant 
increase in cell-free DNA in PMA-stimulated cells (Fig. 4B). We therefore used measurements of cell-free DNA, 
to quantitatively measure DNA released by neutrophils, as an indirect measure of NETosis. We then normalised 
our results against a no IgG control, thus examining any modulatory effects of IgG upon NETosis.
Concurrent with published studies, we also report an increase in spontaneous DNA release by neutrophils in 
the presence of SLE- or RA-IgG compared to HC-IgG (Fig. 4C). Only SLE-IgG however, significantly elevated 
PMA-induced DNA externalisation by neutrophils in the absence of endothelial cells (Fig. 4C).
We then studied neutrophil DNA release in co-culture with either steady-state or TNF-α-activated HUVEC 
to model the cellular interactions that would occur with the vascular endothelium. Interestingly, co-culture of 
neutrophils with steady-state HUVEC abrogated the increases in both spontaneous and PMA-induced DNA 
release that we observed with neutrophils stimulated in the absence of endothelial cells (Fig. 4D). However, when 
HUVEC were activated with TNF-α prior to co-culture, SLE-IgG, but not RA-IgG, significantly increased both 
spontaneous and PMA-induced DNA externalisation (Fig. 4E).
Discussion
Abnormalities in neutrophil function contribute to the immunopathology of several ARDs, including SLE and 
RA. Whilst neutrophils isolated from patients with SLE and RA have been shown to exhibit increased propensi-
ties to release NETs, it is not known whether pathogenic autoantibodies directly engage and drive neutrophil dys-
function. We report that whole SLE- and RA-IgG fractions have differential binding to neutrophils in vitro, and 
further demonstrate that ARD-IgG enhance ROS production and DNA release, suggestive of enhanced NETosis. 
Taken together, these data suggest that ARD-IgG may act as priming agents that enhance neutrophil activation 
following stimulus.
Many groups have sought to identify the surface molecules implicated in IgG-mediated leukocyte dysfunction. 
Due to the wealth of potential autoantigens associated with both SLE and RA, identification of a singular antigen 
target has been met with varying degrees of success and is likely to be completely different in both disease groups. 
We initially assessed the role of FcγRs, given that immune complexes can interact with neutrophil FcγRs71 and 
induce ROS generation72. Indeed, SLE-IgG binding was reduced following FcγR blockade, indicating a degree of 
FcγR-mediated binding. This reduction may indicate a contribution of FcγR-mediated effects to neutrophil activa-
tion in patients with SLE. In our further experiments however, we assessed the antigen-specific effects of purified 
IgG in the presence of FcγR blockade, we found that both SLE- and RA-IgG were able to enhance β1 integrin activa-
tion, measured by adhesion to immobilised fibronectin, but only SLE-IgG significantly enhanced αMβ2-mediated 
adhesion to PMA stimulated neutrophils. These differences in integrin activation may highlight a subtle form of 
Figure 2. SLE- IgG enhances both neutrophil β1 and β2 integrin activation. BCECF-AM labelled neutrophil 
adhesion to immobilised integrin ligands was assessed in the presence of purified IgG to evaluate integrin 
activation. (A) 20 μg/ml fibronectin was immobilised and neutrophil adhesion examined in the absence or 
presence of 20 nM PMA and the 10 μg/ml pan-β1 integrin blocking antibody P5D2. (B) 200 μg/ml fibrinogen 
was immobilised and neutrophil adhesion evaluated in the absence or presence of 20 nM PMA and the 10 μg/ml 
αMβ2-specifc blocking antibody 2LPM19c. In both cases, data are presented as the mean and SEM from three 
independent experiments and analysed by two-way ANOVA with a Dunnett’s multiple comparison test. 
*p < 0.05, **p < 0.01.
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differential regulation by different ARD-IgG upon steady-state and PMA stimulated neutrophils. In this model, it is 
possible that the presence of ARD-IgG is able to enhance integrin affinity and/or avidity further than that seen with 
PMA alone. This enhancement may allow for different integrin families to either adopt a high affinity conformation 
or undergo integrin clustering and therefore allow high avidity interactions with integrin ligands.
Our experiments utilised immobilised fibronectin and fibrinogen, which are found in areas of tissue injury with 
local activation of coagulation and in regions of vascular endothelial damage where the sub-endothelial basement 
membrane has been exposed. Our choice of ligands has the advantage of readily allowing us to distinguish the effects 
of IgG on β1-mediated adhesion to ECM/VCAM-1 from the effects on αMβ2-mediated adhesion. Given the wealth 
of literature on ligand binding motifs, it is reasonable to extrapolate our findings to other integrin ligands for αMβ2 
and α4β1, such as ICAM-1 and VCAM-1 that play a key role in neutrophil-endothelial interactions. Future work will 
be aimed at dissecting these ligand preferences further. It is also possible that augmented integrin-mediated binding 
occurs within the circulation. Fibronectin can be found incorporated into circulating NETs that can promote further 
neutrophil interactions73,74, circulating in plasma, as well as forming a constituent of basement membranes and 
ECM75. In addition, the finding of increased circulating apoptotic endothelial cells in patients with SLE76, would 
provide further endothelial integrin ligands to engage circulating leukocytes within the blood flow.
We found a similar pattern of differential activation with ROS generation, a process requiring αMβ277, that 
was increased by RA- and SLE-IgG. The requirement of αMβ2, whose affinity is commonly reduced in SLE78, may 
underlie our observation of reduced ROS in ex vivo SLE-derived neutrophils. Differences in treatment regimens 
between groups may also account for the reduced rates of H2O2 generation. If we consider both the myelosuppres-
sive and immunosuppressive effects of mycophenolate mofetil and prednisolone, as well as their half-lives (17.6 
and 2.6 hours respectively)79,80, which all SLE patients were prescribed, it is possible that the activity of freshly 
isolated neutrophils may still be pharmacologically suppressed. Alternatively, reduced H2O2 production may be a 
result of metabolic exhaustion arising from systemic activation prior to cell isolation.
Figure 3. SLE- IgG increased neutrophil adhesion to endothelial cells, but not trans-endothelial migration. 
BCECF-AM labelled neutrophil adhesion was assessed in the absence or presence of purified IgG and 20 nM 
PMA to (A) resting endothelial cells and (B) endothelial cells that had been activated with TNF-α prior 
to experimentation. (C) Fluorescently labelled neutrophil trans-endothelial migration was determined in 
the absence or presence of purified IgG and 150 ng/ml IL-8, using a trans-well cell culture system and flow 
cytometry. Cells were quantified by comparing enumerated cells in the lower chamber to the total cells added. 
In both cases, data are displayed as the mean and SEM of three independent experiments and were tested for 
significance using two-way ANOVA with a Dunnett’s multiple comparison test. **p < 0.01, ****p < 0.0001.
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Integrin activation is central to leukocyte migration, therefore we examined whether ARD-IgG affected neu-
trophil adhesion to, and migration across, the endothelium. Interestingly, SLE-IgG, but not RA-IgG, significantly 
augmented neutrophil adhesion to HUVEC, while migration across an IL-8 gradient was unaffected by ARD-IgG. 
Figure 4. SLE- IgG increased neutrophil NETosis in the presence of endothelial cells. (A) PMA-induced 
NETosis was confirmed by immunofluorescence. Neutrophils were incubated on coverslips in the absence 
or presence of 40 nM PMA and then fixed. Coverslips were then stained for histone H3 and mounted using 
a DAPI-mounting medium. (B) Cell supernatants from neutrophils cultured in the absence or presence of 
40 nM were analysed using the Quanti-iT PicoGreen dsDNA kit. Data are presented as the mean and SEM 
of three independent experiments. Statistical significance was determined by a Mann-Whitney test. (C–E) 
IgG-mediated extracellular DNA release was assessed in (C) the absence of an endothelial monolayer; (D) 
the presence of resting endothelial cells; and (E) the presence of activated endothelial cells. Neutrophils were 
cultured for 4 hours in the absence or presence of 40 nM PMA, after which cell supernatants were assessed 
for cell-free dsDNA. For endothelial cell activation, HUVEC were pre-stimulated with 10 ng/ml TNF-α for 
24 hours and washed with warmed PBS prior to addition of neutrophils. Data are presented as the mean and 
SEM of three independent experiments and analysed using a two-way ANOVA with a Dunnet’s multiple 
comparison test. *p < 0.05, **p < 0.01, ****p < 0.0001.
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This observation may suggest that the primary effects of ARD-IgG centre on the firm adhesion stage of leukocyte 
extravasation, as opposed to enhancing both adhesion and trans-endothelial migration. Interestingly, we also 
noted differences in unstimulated adhesion, with no significant differences observed to immobilised fibronectin 
or fibrinogen but increased baseline adhesion to HUVEC in the presence of SLE-IgG. This difference may be 
explained by the presence of numerous additional adhesion molecules on the endothelial monolayer, which are 
absent in immobilised integrin ligand. For examples, endothelial cells would also express ICAM-1 and ICAM-2, 
which are ligands for both αLβ2 and αMβ2 on the neutrophil. These differences highlight the complex interactions 
occurring between integrins and adhesion molecules under physiological conditions.
Endothelial co-culture modulated the ARD-IgG effects on NETosis. In particular, the presence of a quies-
cent endothelium abrogated the effects of SLE- and RA-IgG on DNA externalisation observed in the absence of 
endothelial cells. Stimulation of the endothelium however, restored elevated SLE-IgG induced NETosis, impli-
cating an endothelial contribution. These results may indicate that the presence of ARD-IgG may enhance neu-
trophil interactions with their external environment and promote neutrophil activation to regions of endothelial 
activation and dysfunction. A limitation to these experiments is the use of cell-free DNA as an indirect measure-
ment of NETosis. Whilst our approach allowed us to quantitatively compare DNA externalisation to assess the 
effects upon NETosis, we lose the ability to specifically assess for markers widely accepted to be associated with 
NET structure, such as citrullinated histones and MPO. The development of a quantitative NET standard to allow 
the precise measurements of DNA-protein constructs accepted as NETs would resolve this issue.
We administered FcR blockade in our experiments to focus upon the antigen-specific nature of our obser-
vations. To further study this interaction additional experiments could be performed using F(ab′)2 frag-
ments to ensure cellular effects were mediated solely through antigen-specific binding. Differences in IgG 
post-translational modifications of the Fc region may also contribute to the physiological effects of IgG. In par-
ticular, modifications such as glycosylation and sialylation are believed to mediate cellular effects of IgG81–85, and 
may potentially account for differences between ARD- and HC-IgG. Future experiments however, are required 
to explore the contribution of any differences in post-translational modifications between IgG groups and were 
beyond the scope of this study.
These different patterns of IgG-mediated integrin activation and neutrophil function may help elucidate the 
differential mechanisms driving vascular damage and dysfunction in these different ARDs. In conclusion, we 
found a differential pattern of autoantibody binding and integrin activation in steady-state and stimulated neutro-
phils exposed to purified whole IgG from patients with SLE or RA, which was modulated by the activation state of 
the endothelium (Fig. 5). Further work is now underway to explore the translational implications of our findings 
to highlight novel therapeutic targets.
Materials and Methods
patients. Whole blood and serum were obtained by informed consent from 33 patients fulfilling classifica-
tion criteria; 16 RA86 and 17 SLE87, as well as 21 HCs. Ethical approval was given by the UK National Research 
Ethics Committee and NHS Permission was granted for the study to be undertaken at University College London 
Hospitals NHS Foundation Trust (IRAS ID: 39531; REC Ref: 13/LO/0900; CSP number 39531) and all experi-
mental procedures were performed in accordance with the Declaration of Helsinki and compliant with the prin-
ciples of Good Clinical Practice.
Figure 5. Schematic of overall findings. SLE- and RA-IgG displayed differential effects upon HC-neutrophils 
in our experiments. SLE-IgG enhanced both β1 and β2 integrin-mediated adhesion and also adhesion to 
endothelial cells. In contrast, RA-IgG only increased β2 integrin-mediated adhesion. We observed higher levels 
of NETosis both in absence and presence of activated endothelial cells with the addition of SLE-IgG, whilst RA-
IgG only enhanced NETosis in the absence of an endothelial monolayer.
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IgG purification. Whole IgG was purified by passing patient or HC serum through protein G agarose spin 
columns (Thermo Scientific, UK) and eluted using 0.1 M glycine (Sigma, UK). Eluted IgG was concentrated, 
washed and dialysed into endotoxin-free PBS by sequential centrifugations for 20 minutes at 2050 g using cen-
trifugal filter units (Merck Millipore, Ireland). Concentrated IgG was then passed through endotoxin removal 
columns (Thermo Scientific, UK) and confirmed to be endotoxin-free by EndoLISA (Hyglos, Germany) (<0.06 
endotoxin units/ml).
Autoimmune rheumatic disease-associated IgG binding characterisation. Titres of ACPA 
in purified IgG samples were quantified using the EDIA anti-CCP-2 kit (Euro Diagnostica, Sweden). Titres of 
PR3-ANCA and MPO-ANCA in purified IgG were determined using the WIESLAB ANCA screen kit (Euro 
Diagnostica, Sweden). Quantification of anti-nuclear antibodies (ANA), anti-double stranded DNA antibod-
ies (anti-dsDNA) and rheumatoid factor (RF) were all performed in the University College London Hospital 
laboratory.
Neutrophil isolation. Citrated whole blood was obtained by venepuncture and red blood cells removed 
by dextran sedimentation for 45 minutes. Neutrophils were isolated from the cell-enriched plasma by Percoll 
PLUS (Sigma, UK) gradient centrifugation at 700 g for 30 minutes and resuspended in phenol-free RPMI 
(Thermo Scientific, UK) supplemented with 10% FCS (Thermo Scientific, UK) and 2mM L-glutamine (Lonza, 
Switzerland). Isolated neutrophils were counted using a 0.4% Trypan Blue solution and diluted to 2 × 106 neutro-
phils/ml to ensure the same number of viable cells were used between groups and experiments. For experiments 
examining the effects of IgG, cells were treated with a FcR blocking reagent (Miltenyi, UK) (2 μl per 1 × 106 neu-
trophils) for 20 minutes prior to addition of 200 μg/ml purified IgG.
Endothelial cell culture. HUVEC at passage 2 (P2) (Lonza, Switzerland) were cultured in endothelial 
growth media 2 (Lonza, Switzerland) with 10% FCS (Thermo Scientific, UK) and 2mM L-glutamine (Lonza, 
Switzerland) to P5 for all experimental procedures. For endothelial activation, HUVEC were treated with 10 ng/
ml TNF-α (R&D Systems, UK) for 24 hours and then washed with warmed HBSS prior to experimentation.
IgG binding. Neutrophils were cultured with 200 μg/ml IgG for 2 hours, fixed in 2% paraformaldehyde (PFA) 
(Sigma, UK) for 15 minutes, and stained using PE-conjugated anti-CD15 (clone W6D3) and FITC-conjugated 
anti-human IgG (clone G18-145) (BD Biosciences, UK) for 30 minutes at room temperature in the dark. Stained 
cells were washed twice in a sodium HEPES buffer (20 mM HEPES, 140 mM NaCl, 2 mg/ml glucose, 0.3% BSA) 
and analysed using a FACSVerse (BD Biosciences). Resulting data was analysed using FlowJo (TreeStar Inc., UK). 
IgG binding was calculated as the percentage of CD15+ neutrophils that were also positive for human IgG.
Neutrophil adhesion. Fibronectin (Sigma, UK) (for β1 integrin engagement) and fibrinogen (Sigma, UK) 
(for αMβ2 integrin engagement) were immobilized in 96-well black MaxiSorp microplates (Thermo Scientific, 
UK) and blocked with 2% fish-skin gelatin (Sigma, UK), to reduce non-specific neutrophil binding (Fig. S1). 
HUVEC were cultured in 96-well black tissue culture plates (Thermo Scientific, UK). HC-neutrophils were 
labelled with 2.5 μM 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluoresceinacetoxymethyl ester (BCECF-AM) 
(Life Technologies, UK) for 30 minutes at 37 °C. Stained cells were washed twice in the sodium HEPES buffer by 
centrifugation at 300 g for 5 minutes and resuspended to 1 × 107 neutrophils/ml. 5 × 105 neutrophils were added 
to wells containing 20 nM PMA and 200 μg/ml IgG for 30 minutes at 37 °C. Fluorescence was measured using a 
Tecan GENios Spectra FLUOR plate reader (Tecan UK Ltd., UK). Plates were washed and read again. Adhesion 
was calculated by comparing the fluorescence of washed wells to initial fluorescence.
Neutrophil trans-endothelial migration. HUVEC were grown to confluence on transwell inserts 
(Millipore, UK). HC-neutrophils were isolated, washed with M199 media (Invitrogen, UK) labelled with a 0.5 µM 
CellTracker (Invitrogen, UK). Labelled cells were washed with M199 media by centrifugation at 300 g for 5 min-
utes and resuspended to 5.5 × 106 neutrophils/ml in M199 media supplemented with 1% FCS. Transwells were 
washed with M199 and 1.1 × 106 neutrophils added to the upper chamber. Transmigration was assessed both in 
the absence or presence of 150 ng/ml IL-8 in the lower chamber for 90 minutes. Migration was evaluated by flow 
cytometry, using CountBright absolute counting beads (Invitrogen, UK) to enumerate the number of cells in the 
lower chamber. Percent transmigration was calculated by comparing the number of cells in the lower chamber 
and the number of neutrophils added to the upper chamber.
Hydrogen peroxide generation. 2 × 106 HC-neutrophils were incubated with 200 μg/ml IgG for 1 hour at 
37 °C before addition of 0.5U/ml HRP (Sigma, UK) and 60 nM Amplex UltraRed (Invitrogen, UK). 4 × 105 cells 
were added to each test well of a 96-well black microplate (Thermo Scientific, UK) and fluorescence measured 
by FLUOstar Omega microplate reader (BMG Labetech, Germany). H2O2 generation in response to 50 nM PMA 
was recorded over time and rates (expressed in nM/sec) determined using Omega Mars Analysis software (BMG 
Labtech, Germany). In separate experiments, H2O2 generation was assessed in patient- and HC-derived neutro-
phils, however in the absence of autologous IgG.
Immunofluorescence staining for neutrophil extracellular traps. Glass coverslips (Fischer, UK) were 
sterilized with and coated with 200 μg/ml fibrinogen (Sigma, UK) at 4 °C. 5 × 105 neutrophils were then added to 
coverslips and stimulated for 4 hours, after which they were fixed for 15 minutes with 4% PFA at room tempera-
ture. Coverslips were blocked in a blocking solution (10% goat serum/1% BSA/2 mM EDTA/HBSS/0.1% Tween-2) 
overnight at 4 °C, then incubated with 1 µg/ml anti-histone H3 antibody (ab1791, Abcam, UK) and then 2 µg/ml 
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Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody (Life Technologies, UK), which were 
diluted in blocking solution, for one hour each at room temperature. After incubations, coverslips were washed 
with HBSS twice, mounted and sealed on microscope slides with ProLong Gold antifade mountant with DAPI 
(Invitrogen, UK). Slides were subsequently visualized using a Zeiss Axio Imager.A1 inverted fluorescence micro-
scope (Zeiss, Germany) and images analysed using Image J.
Extracellular DNA quantification. HC-neutrophils were pre-treated with IgG for 1 hour, after which 
NETosis was induced by stimulation with 40 nM PMA for 4 hours. Neutrophil supernatants were obtained by 
centrifugation at 300 g for 5 minutes and then assessed for extracellular DNA using the Quanti-iT PicoGreen 
dsDNA kit (Invitrogen, UK). Results were then normalised to a no IgG control, thus examining any modulatory 
effects of IgG.
Statistical analysis. Data were evaluated using GraphPad Prism. Data were first tested for normality using a 
Kolmogorov-Smirnov test. In experimental data sets only comparing two groups, a Mann-Whitney test was per-
formed. Where multiple groups were being compared, a Kruskal-Wallis test with a Dunn’s multiple comparison 
test was used. In data sets with two variables, data were assessed by two-way ANOVA with a Dunnet’s multiple 
comparison test. A p value below 0.05 was considered significant.
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